ON-DEMAND WEBINAR

Patents, Vaccines, and Viruses: A conversation about the role of IP in the age of COVID-19

GABY L. LONGSWORTH
Director
Sterne, Kessler, Goldstein & Fox P.L.L.C.
DOREEN ALBERTS
Senior Director of Product Strategy and Commercial Planning
Theravance Biopharma US, Inc.
ANDREA DAVIS
Managing Director
Bodkin IP
TONY TRIPPE
Managing Director
Patinformatics
SANDEEP THAKUR
Head of Biopharma IP Product Management
Clarivate Analytics

As the coronavirus pandemic spreads across the globe, putting unprecedented pressure on social, health, and economic systems, scientists are working around the clock to develop vaccine candidates in record time.

Intellectual property in the form of patented biosequences and chemical structures may play a role in inhibiting or antagonizing the virus factor to help researchers better understand the disease and bring treatments to fruition.

These extraordinary, collaborative, and fast-tracked scenarios playing out in labs all over the world raise some important questions for the biopharma patent community with regard to the state of innovation for the public good, today and in the future.

We will be covering the following topics

  • How are patent gene sequences and chemical structures impacting vaccine development today versus a decade ago? What role will they play in the future?
  • What can past responses to global pandemics teach us about the importance and management of intellectual property now?
  • What impact has the current climate had on IP activity more generally across the globe and how can patent practitioners guide organizations to create and maintain innovation momentum? ​​